4.325
1.00%
-0.045
전일 마감가:
$4.37
열려 있는:
$4.35
하루 거래량:
592.63K
Relative Volume:
0.14
시가총액:
$564.43M
수익:
-
순이익/손실:
$-110.78M
주가수익비율:
-4.0421
EPS:
-1.07
순현금흐름:
$-75.59M
1주 성능:
-5.13%
1개월 성능:
-15.17%
6개월 성능:
-45.03%
1년 성능:
+29.14%
Humacyte Inc Stock (HUMA) Company Profile
명칭
Humacyte Inc
전화
919-313-9633
주소
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
HUMA을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
4.32 | 564.43M | 0 | -110.78M | -75.59M | -1.07 |
VRTX
Vertex Pharmaceuticals Inc
|
486.91 | 125.43B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
713.87 | 76.60B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
669.12 | 39.57B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
276.05 | 35.33B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
122.41 | 28.08B | 3.30B | -501.07M | 1.03B | -2.1146 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-12-20 | 재확인 | H.C. Wainwright | Buy |
2023-12-11 | 개시 | H.C. Wainwright | Buy |
2023-08-14 | 업그레이드 | Piper Sandler | Underweight → Neutral |
2023-06-22 | 개시 | Cantor Fitzgerald | Overweight |
2022-05-16 | 다운그레이드 | Piper Sandler | Overweight → Underweight |
2021-10-29 | 개시 | Cowen | Outperform |
2021-09-24 | 개시 | Oppenheimer | Outperform |
2021-09-22 | 개시 | BTIG Research | Buy |
2021-09-16 | 개시 | Piper Sandler | Overweight |
모두보기
Humacyte Inc 주식(HUMA)의 최신 뉴스
Humacyte, Inc. (HUMA) Laps the Stock Market: Here's Why - MSN
Investing in Humacyte Inc (HUMA) Is Getting More Attractive - Knox Daily
Financial Analysis: Humacyte Inc (HUMA)’s Ratios Unveil Key Insights - The Dwinnex
Examining Humacyte Inc (HUMA) more closely is necessary - US Post News
Wealth Effects LLC Buys 57,200 Shares of Humacyte, Inc. (NASDAQ:HUMA) - MarketBeat
Humacyte (NASDAQ:HUMAW) Trading Down 1% – What’s Next? - Defense World
Why Is Bioengineered Human Tissue-Focused Humacyte Stock Surging On Friday? - AOL
Humacyte and Pluristyx enhance partnership for diabetes treatment By Investing.com - Investing.com South Africa
Humacyte, Pluristyx Announce Gene Editing Partnership -January 28, 2025 at 12:05 pm EST - Marketscreener.com
Humacyte and Pluristyx enhance partnership for diabetes treatment - Investing.com India
Humacyte and Pluristyx Announces Gene Editing Partnership to Support BioVascular Pancreas (BVP?) Development Using iPSCs - Marketscreener.com
Humacyte and Pluristyx Announce Gene Editing Partnership to Support BioVascular Pancreas (BVP™) Development Using iPSCs - The Manila Times
Revolutionary Diabetes Breakthrough: Gene-Edited Cell Technology Could End Daily Insulin Injections - StockTitan
2 Firms Want To Co-Lead Humacyte Investor Suit - Law360
Humacyte, Inc. (HUMA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Humacyte: Upside Potential, But I Will Wait For Revenue Trends - Seeking Alpha
Cantor Fitzgerald Comments on Humacyte FY2025 Earnings - Defense World
Humacyte’s (HUMA) “Buy” Rating Reiterated at D. Boral Capital - Defense World
HUMACYTE ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
Humacyte, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky Before January 17, 2025 to Discuss Your RightsHUMA - ACCESS Newswire
Cantor Fitzgerald Estimates Humacyte FY2025 Earnings - MarketBeat
Humacyte moves to test bioengineered vessel in heart surgery - MSN
Humacyte moves to test bioengineered vessel in heart surgery By Investing.com - Investing.com Australia
DEADLINE ALERT for WOLF, HUMA, XRX, and ZETA: The Law - GlobeNewswire
DEADLINE ALERT for WOLF, HUMA, XRX, and ZETA: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders - GlobeNewswire Inc.
Humacyte (NASDAQ:HUMA) Given Buy Rating at D. Boral Capital - MarketBeat
Humacyte Announces Planned IND Filing in 2025 to Support First-In-Human Clinical Study of Small-Diameter ATEV™ for Coronary Artery Bypass Grafting - The Manila Times
Humacyte Announces Planned IND Filing in 2025 to Support - GlobeNewswire
Humacyte Sends First Shipment of Human Acellular Vessels to Ukraine as Part of Humanitarian Efforts - Fresenius Medical Care
11,105 Shares in Humacyte, Inc. (NASDAQ:HUMA) Acquired by Brookstone Capital Management - Defense World
Humacyte (NASDAQ:HUMA) Stock Price Up 10%Time to Buy? - MarketBeat
Cantor Fitzgerald Boosts Earnings Estimates for Humacyte - Defense World
Humacyte FY2024 EPS Forecast Raised by Cantor Fitzgerald - MarketBeat
Humacyte (NASDAQ:HUMA) Stock Price Down 6.4%What's Next? - MarketBeat
Class Action Filed Against Humacyte, Inc. (HUMA)January 17, 2 - GuruFocus.com
Faruqi & Faruqi Reminds Humacyte Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 17, 2025HUMA - PR Newswire
HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
HUMA DEADLINE TODAY: ROSEN, A TOP RANKED LAW FIRM, - GlobeNewswire
HUMA DEADLINE TODAY: ROSEN, A TOP RANKED LAW FIRM, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important January 17 Deadline in Securities Class Action - GlobeNewswire Inc.
HUMA Deadline: Rosen Law Firm Urges Humacyte, Inc. (NASDAQ: HUMA) Stockholders with Large Losses to Contact the Firm for Information About Their Rights - Business Wire
Faruqi & Faruqi Reminds Humacyte Investors of the Pending - GlobeNewswire
Cantor Fitzgerald Predicts Higher Earnings for Humacyte - MarketBeat
Levi & Korsinsky Notifies Humacyte, Inc. Investors of a Class Ac - GuruFocus.com
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte - Markets Insider
2025-01-16 | HUMA LAWSUIT ALERT: Levi & Korsinsky Notifies Humacyte, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline | NDAQ:HUMA | Press Release - Stockhouse Publishing
Humacyte, Inc. Class Action: Levi & Korsinsky Reminds Humacyte, - GuruFocus.com
Shareholders that lost money on Humacyte, Inc.(HUMA) should - GlobeNewswire
Humacyte, Inc. (NASDAQ:HUMA) Short Interest Update - MarketBeat
Humacyte, Inc. (HUMA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
HUMA Lawsuit Alert! Class Action Against Humacyte, Inc. - TipRanks
The Gross Law Firm Notifies Shareholders of Humacyte, Inc.(HUMA) of a Class Action Lawsuit and an Upcoming Deadline - Marketscreener.com
Humacyte Inc (HUMA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):